Standout Papers

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Pro... 2019 2026 2021 2023 414
  1. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy (2019)
    Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
3 intermediate papers

Works of Juan Pinelli being referenced

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019 Standout
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
2017

Author Peers

Author Last Decade Papers Cites
Juan Pinelli 306 99 154 322 8 625
Ordóñez Ng 177 115 65 297 10 657
Robert G. Somers 149 118 172 187 13 616
Dominique Cazals 66 136 142 245 11 515
Billur Şamli 107 134 181 239 13 574
Don W. Shaffer 115 138 266 401 11 666
Kathrin Glatz 128 97 54 330 12 572
Houda Boukheris 246 62 65 331 10 561
Carol L. Shields 125 71 90 160 10 644
S Khorana 82 185 62 240 12 634
Bing B Fung 278 60 47 178 7 580

All Works

Loading papers...

Rankless by CCL
2026